Glenmark Pharmaceutical is currently trading at Rs. 514.75, up by 1.15 points or 0.22 % from its previous closing of Rs. 513.60 on the BSE.
The scrip opened at Rs. 514.90 and has touched a high and low of Rs. 518.90 and Rs. 507.90 respectively. So far 66728 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 550.80 on 09-Jan-2013 and a 52 week low of Rs. 286.15 on 07-Mar-2012.
Last one week high and low of the scrip stood at Rs. 534.60 and Rs. 485.05 respectively. The current market cap of the company is Rs. 13946.02 crore.
The promoters holding in the company stood at 48.32 % while Institutions and Non-Institutions held 40.01 % and 11.67 % respectively.
Glenmark Pharmaceuticals S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) has discovered and initiated IND enable studies of a novel clinical development candidate, GBR 830, an anti-OX40 monoclonal antibody.
GBR 830 has been discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 830, an anti-OX40 monoclonal antibody is a potential Global First-in-class molecule
OX40 is a well known target and the development of OX40 antagonists has been very challenging. The company has achieved a significant milestone with the successful generation of an antagonistic OX40 monoclonal antibody coupled with generation of data validating the role of OX40 in autoimmune diseases.
GBR 830 shows great promise to emerge as a valuable therapeutic option to treat patients suffering from immune pathologies such as autoimmune diseases like Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD).
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1826.10 |
Dr. Reddys Lab | 1371.60 |
Cipla | 1488.15 |
Lupin | 2251.80 |
Zydus Lifesciences | 1009.40 |
View more.. |